Skip Navigation
Search Menu
Radiology and Radiological Science

In This Section      

Canine Prostate Cancer Clinical Trial

Study Title: PET-CT Evaluation of Metastatic Prostate Cancer using 18F DCF-Pyl
Current Status: Open and enrolling
Principle Investigators: Rebecca A. Krimins, D.V.M., M.S.rkrimin1@jhmi.eduDara L. Kraitchman, V.M.D., Ph.D.,

Contact us for more information about this clinical trial.

This is a clinical trial that will enroll a total of 5-7 dogs in order to confirm that 18F DCF-Pyl PET-CT offers an improved sensitivity for the early detection of metastatic prostate cancer. Safety and toxicology studies have been performed in healthy dogs. This is the first trial using 18F DCF-Pyl (a novel radiotracer) for evaluation in dogs with prostate cancer.

Clinical trial summary handout | Clinical trial details handout

Selection of Participants

Any male dog (castrated or intact) of any breed will be eligible. Eligible dogs will have undergone a thorough medical workup at their local veterinary hospital. Results from medical records, radiographs, ultrasounds, complete blood counts, serum chemistries, urinalyses and histopathology of the prostatic lesion will be used to determine if a dog is eligible for this trial. In addition, each pet owner must sign an informed consent form in order for his/her dog to participate in the clinical trial.

Participating dogs should meet the following criteria:

  • The patient is at low risk for an adverse response to general anesthesia (ASA physical classification status I, II or III).


  1. The patient will have undergone a thorough workup at their local veterinary hospital.
  2. After confirmation of suspect prostate cancer, the study will provide a PET-CT scan (whole body) to determine the patient's burden of metastatic prostate cancer.
  3. This trial involves a diagnostic test only.

Cost of Studies

Owners are responsible for their dog's initial workup. The study pays for a whole-body PET-CT using 18F DCF-Pyl at the Center for Image-Guided Animal Therapy.

Contact Us

To find out more about this clinical trial, send an email to or call 410-502-7325.